Linking up with Dr. Mercola: Patients with severe mental illness are approximately three times more likely to die from cardiovascular disease than those without these conditions. Some psychiatric medications for severe mental illness are associated with potentially harmful effects on the heart and blood vessels.
This review highlights the short- and long-term adverse cardiovascular effects of psychiatric medications. These adverse effects include QTc interval prolongation and polymorphic ventricular tachycardia (torsades de pointes), phenomena associated with certain selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and antipsychotics. Increased QT dispersion and induction of the Brugada phenotype, both associated with serious cardiac arrhythmias and sudden death, can occur with certain antipsychotics (e.g., trifluoperazine), certain tricyclic antidepressants (TCAs) (e.g., amitriptyline), certain SSRIs (e.g., fluoxetine), methylphenidate, and certain mood stabilizers (e.g., lithium). The antipsychotics themselves are associated with an increased risk of myocarditis, cardiomyopathy, tachycardia, cardiometabolic disturbance, hypertension, orthostatic hypotension, and bradycardia. Medications for attention-deficit/hyperactivity disorder (ADHD) contribute to cardiovascular disease and tachycardia. Acetylcholinesterase inhibitors (AChE inhibitors) contribute to bradycardia. The risk of hypertension increases with serotonin-norepinephrine reuptake inhibitors (SNRIs), dopamine-norepinephrine reuptake inhibitors (NDRIs), monoamine oxidase inhibitors (MAOIs), reversible monoamine oxidase A inhibitors (RIMAs), and psychostimulants. Conversely, orthostatic hypotension is associated with certain psychiatric medications, particularly tricyclic antidepressants (TCAs) and serotonin antagonists and reuptake inhibitors (SARIs). It is important to note that pharmacokinetic interactions, such as inhibition of the cytochrome P450 (CYP450) system, can affect the pharmacodynamic profile of psychiatric medications, thereby increasing the risk of their adverse cardiovascular effects.
In elderly patients undergoing coronary artery bypass graft surgery, immediate discontinuation of anticholinergic medication in the perioperative period improved functional recovery at 90 days and was associated with fewer cardiac and pulmonary complications. Anticholinergic burden could represent a modifiable perioperative risk factor that should be systematically addressed in surgical care protocols to optimize outcomes in older adults.
Another really Big WoW! No small potatoes study this one either. One more well yes this 'medicine' does this one thing, but what else might it do? How does it fare long term? Even if taken for a short time, will it have negatives later on? Then too may we wonder would such a study even occur here in the States? Also, do we really have to wonder just how long Legacy Media, the Official Gate Keepers will attack this study with whatever they can hang their hat on, or if need be, pull a Fauci make something up. Such questions, explorations into these territories are questions those who are seeking Health Building, Dis-Ease Preventions affording longer and best quality lives are attacked by a system set into motion over a hundred years ago to blunt such in favor of consuming customers and never ending treadmill treatments for life addressing symptoms. Such has encouraged a public to endorse the notion - give me a pill so I can continue to keep doing the very thing/things that are making me sick.
Very true, JUST, it's the disease industry sustained by a diet of processed foods and unhealthy lifestyles, where the only thing that matters is selling. Pharmaceutical companies spent US$1.68 billion on advertising campaigns in 2025 for just the 10 most advertised medications, including the famous weight-loss antidiabetic Ozempic and other compounds to treat everything from nasal polyps to rheumatoid arthritis. Medications with serious side effects. It's unbelievable.
Direct-to-consumer advertising of these prescription drugs is prohibited in every country in the world except the United States and New Zealand.
Advertising prescription drugs hasn't always been legal in the United States. Until the 1990s, as in almost every country in the world, pharmaceutical companies directed their advertising and marketing efforts exclusively to doctors. But the paradigm shifted in the last decade of the 20th century because other players emerged in the healthcare sector, such as insurers; pharmaceutical companies became much more powerful; and the rise of the consumer movement helped empower patients to make their own decisions,” reports researcher Jeanne Madden, a healthcare systems expert at Northeastern University in Boston.
Linking up with Dr. Mercola: Patients with severe mental illness are approximately three times more likely to die from cardiovascular disease than those without these conditions. Some psychiatric medications for severe mental illness are associated with potentially harmful effects on the heart and blood vessels.
This review highlights the short- and long-term adverse cardiovascular effects of psychiatric medications. These adverse effects include QTc interval prolongation and polymorphic ventricular tachycardia (torsades de pointes), phenomena associated with certain selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and antipsychotics. Increased QT dispersion and induction of the Brugada phenotype, both associated with serious cardiac arrhythmias and sudden death, can occur with certain antipsychotics (e.g., trifluoperazine), certain tricyclic antidepressants (TCAs) (e.g., amitriptyline), certain SSRIs (e.g., fluoxetine), methylphenidate, and certain mood stabilizers (e.g., lithium). The antipsychotics themselves are associated with an increased risk of myocarditis, cardiomyopathy, tachycardia, cardiometabolic disturbance, hypertension, orthostatic hypotension, and bradycardia. Medications for attention-deficit/hyperactivity disorder (ADHD) contribute to cardiovascular disease and tachycardia. Acetylcholinesterase inhibitors (AChE inhibitors) contribute to bradycardia. The risk of hypertension increases with serotonin-norepinephrine reuptake inhibitors (SNRIs), dopamine-norepinephrine reuptake inhibitors (NDRIs), monoamine oxidase inhibitors (MAOIs), reversible monoamine oxidase A inhibitors (RIMAs), and psychostimulants. Conversely, orthostatic hypotension is associated with certain psychiatric medications, particularly tricyclic antidepressants (TCAs) and serotonin antagonists and reuptake inhibitors (SARIs). It is important to note that pharmacokinetic interactions, such as inhibition of the cytochrome P450 (CYP450) system, can affect the pharmacodynamic profile of psychiatric medications, thereby increasing the risk of their adverse cardiovascular effects.
https://journals.sagepub.com/doi/full/10.1177/20420986261418947 (2026)
In elderly patients undergoing coronary artery bypass graft surgery, immediate discontinuation of anticholinergic medication in the perioperative period improved functional recovery at 90 days and was associated with fewer cardiac and pulmonary complications. Anticholinergic burden could represent a modifiable perioperative risk factor that should be systematically addressed in surgical care protocols to optimize outcomes in older adults.
https://www.sciencedirect.com/science/article/abs/pii/S1053077026003940 (2026)
Another really Big WoW! No small potatoes study this one either. One more well yes this 'medicine' does this one thing, but what else might it do? How does it fare long term? Even if taken for a short time, will it have negatives later on? Then too may we wonder would such a study even occur here in the States? Also, do we really have to wonder just how long Legacy Media, the Official Gate Keepers will attack this study with whatever they can hang their hat on, or if need be, pull a Fauci make something up. Such questions, explorations into these territories are questions those who are seeking Health Building, Dis-Ease Preventions affording longer and best quality lives are attacked by a system set into motion over a hundred years ago to blunt such in favor of consuming customers and never ending treadmill treatments for life addressing symptoms. Such has encouraged a public to endorse the notion - give me a pill so I can continue to keep doing the very thing/things that are making me sick.
Very true, JUST, it's the disease industry sustained by a diet of processed foods and unhealthy lifestyles, where the only thing that matters is selling. Pharmaceutical companies spent US$1.68 billion on advertising campaigns in 2025 for just the 10 most advertised medications, including the famous weight-loss antidiabetic Ozempic and other compounds to treat everything from nasal polyps to rheumatoid arthritis. Medications with serious side effects. It's unbelievable.
Direct-to-consumer advertising of these prescription drugs is prohibited in every country in the world except the United States and New Zealand.
Advertising prescription drugs hasn't always been legal in the United States. Until the 1990s, as in almost every country in the world, pharmaceutical companies directed their advertising and marketing efforts exclusively to doctors. But the paradigm shifted in the last decade of the 20th century because other players emerged in the healthcare sector, such as insurers; pharmaceutical companies became much more powerful; and the rise of the consumer movement helped empower patients to make their own decisions,” reports researcher Jeanne Madden, a healthcare systems expert at Northeastern University in Boston.
https://www.bbc.com/mundo/articles/c72py7kgy61o